Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide + rhTPO for corticosteroid-resistant or relapsed immune thrombocytopenia
ChiCTR-OIC-17012859Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Guangdong Medical University
- Start
- Oct 2017
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide and recombinant human thrombopoietin in immune thrombocytopenia (ITP), sponsored by The Affiliated Hospital of Guangdong Medical University. Primary endpoint: Platelet count. Started Oct 2017; status: recruiting.
02
Drugs
thalidomiderecombinant human thrombopoietin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ChiCTR-OIC-17012859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17012859.